TrialCancer communications (London, England)2025

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.

Jian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.